Abivax (STU:2X1) Additional Paid-In Capital : €478.91 Mil(As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Abivax Additional Paid-In Capital?

Abivax's quarterly additional paid-in capital increased from Jun. 2023 (€275.38 Mil) to Dec. 2023 (€478.22 Mil) and increased from Dec. 2023 (€478.22 Mil) to Dec. 2024 (€478.91 Mil).

Abivax's annual additional paid-in capital increased from Dec. 2022 (€150.48 Mil) to Dec. 2023 (€478.22 Mil) and increased from Dec. 2023 (€478.22 Mil) to Dec. 2024 (€478.91 Mil).

Abivax Additional Paid-In Capital Historical Data

The historical data trend for Abivax's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Additional Paid-In Capital Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

42.07

107.58

150.48

478.22

478.91

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															107.52	150.48	275.38	478.22	478.91

Abivax Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Abivax Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Abivax's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines